U.S. patent application number 13/588837 was filed with the patent office on 2013-02-14 for modular drug delivery system for minimizing trauma during and after insertion of a cochlear lead.
This patent application is currently assigned to ADVANCED BIONICS, LLC. The applicant listed for this patent is Michael S. Colvin, Michael A. Faltys, Edward H. Overstreet, Jian Xie. Invention is credited to Michael S. Colvin, Michael A. Faltys, Edward H. Overstreet, Jian Xie.
Application Number | 20130041331 13/588837 |
Document ID | / |
Family ID | 41342621 |
Filed Date | 2013-02-14 |
United States Patent
Application |
20130041331 |
Kind Code |
A1 |
Overstreet; Edward H. ; et
al. |
February 14, 2013 |
Modular Drug Delivery System for Minimizing Trauma During and After
Insertion of a Cochlear Lead
Abstract
A system for delivering a therapeutic agent to biological tissue
includes a surgically implantable lead to be inserted into the
biological tissue. The surgically implantable lead includes a
preformed cavity. A modular capsule is configured to be retained
within the preformed cavity. The modular capsule includes a first
therapeutic agent and a second therapeutic agent, wherein the first
therapeutic agent elutes rapidly into the biological tissue and the
second therapeutic agent elutes more slowly into the biological
tissue.
Inventors: |
Overstreet; Edward H.;
(Valencia, CA) ; Xie; Jian; (Stevenson Ranch,
CA) ; Colvin; Michael S.; (Thousand Oaks, CA)
; Faltys; Michael A.; (Valencia, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Overstreet; Edward H.
Xie; Jian
Colvin; Michael S.
Faltys; Michael A. |
Valencia
Stevenson Ranch
Thousand Oaks
Valencia |
CA
CA
CA
CA |
US
US
US
US |
|
|
Assignee: |
ADVANCED BIONICS, LLC
Valencia
CA
|
Family ID: |
41342621 |
Appl. No.: |
13/588837 |
Filed: |
August 17, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12533963 |
Jul 31, 2009 |
8271101 |
|
|
13588837 |
|
|
|
|
12202134 |
Aug 29, 2008 |
8190271 |
|
|
12533963 |
|
|
|
|
60968785 |
Aug 29, 2007 |
|
|
|
Current U.S.
Class: |
604/285 |
Current CPC
Class: |
A61K 45/06 20130101;
A61K 31/573 20130101; A61K 9/0024 20130101; A61K 9/0046 20130101;
A61K 31/573 20130101; A61N 1/0541 20130101; A61K 2300/00
20130101 |
Class at
Publication: |
604/285 |
International
Class: |
A61M 5/00 20060101
A61M005/00 |
Claims
1. A system for delivering a therapeutic agent to biological tissue
comprising: a surgically implantable lead configured to be inserted
into the biological tissue, the surgically implantable lead
comprising a preformed cavity; and a modular capsule configured to
be retained within the preformed cavity, the modular capsule
comprising a first therapeutic agent and a second therapeutic
agent, wherein the first therapeutic agent is configured to rapidly
elute into the biological tissue and the second therapeutic agent
is configured to more slowly elute into the biological tissue.
2. The system of claim 1, wherein the first therapeutic agent has a
higher solubility in aqueous solutions than the second therapeutic
agent.
3. The system of claim 1, wherein the first therapeutic agent
comprises dexamethosone (DEX) salt and the second therapeutic agent
comprises dexamethosone base (DXMb).
4. The system of claim 3, wherein the DEX salt elutes into a
surrounding aqueous solution at higher concentrations than the
DXMb.
5. The system of claim 1, further comprising a permeable membrane
interposed between the biological tissue and therapeutic agents,
wherein the first therapeutic agent in a first portion of the
capsule has greater access to the membrane and elutes through the
membrane in greater proportion than the second therapeutic agent
placed in a second portion of the capsule with lesser access to the
membrane.
6. The system of claim 5, wherein the permeable membrane comprises
least one of porous polytetrafluoroethylene, a silicone membrane,
fluorinated ethylene propylene, or cellulose acetate.
7. The system of claim 1, wherein at least one of the first
therapeutic agent and the second therapeutic agent comprise
microspheres.
8. The system of claim 1, wherein the first therapeutic agent
comprises powered dexamethosone (DEX) salt having a first particle
size and the second therapeutic agent comprises dexamethosone base
(DXMb) having a second different particle size.
9. The system of claim 8, wherein the modular capsule further
comprises a permeable membrane encapsulating the powered DEX salt
and DXMb.
10. The system of claim 1, wherein the modular capsule comprises a
polymer matrix and mixed DXMb and DEX salt particulates.
11. The system of claim 1, wherein the preformed cavity is covered
by porous metal layer comprising a number of porous elution
paths.
12. A system for delivering a therapeutic agent to biological
tissue comprising: a surgically implantable lead configured to be
inserted into the biological tissue, the surgically implantable
lead comprising a preformed cavity; and a modular capsule
configured to be retained within the preformed cavity, the modular
capsule comprising a drug release profile when inserted in
biological tissue, the drug release profile comprising a high
initial concentration of a first therapeutic agent and a long term
lower concentration of a second therapeutic agent.
13. A modular capsule for delivering a therapeutic agent to
biological tissue, the modular capsule comprising: a membrane; a
first portion comprising a first therapeutic agent; and a second
portion comprising a second therapeutic agent; wherein the first
portion has more direct access to the membrane than the second
capsule such that the first therapeutic agent elutes through the
membrane in greater proportion than the second therapeutic
agent.
14. The capsule of claim 13, wherein the first therapeutic agent
comprises dexamethosone (DEX) salt and the second therapeutic agent
comprises dexamethosone base (DXMb).
15. The capsule of claim 13, wherein elution of the first
therapeutic agent comprises a first particle size and the second
therapeutic agent comprises a second particle size.
16. The capsule of claim 13, wherein the modular capsule comprises
a solid tablet comprising DXMb and DEX salt.
17. The capsule of claim 13, wherein the capsule releases
approximately 0.3 to 0.6 micrograms per day of DXMb into cochlear
tissues.
18. The capsule of claim 13, wherein the membrane comprises
polyvinyl alcohol (PVA) and walls of the capsule comprise silicone.
Description
RELATED APPLICATIONS
[0001] The present application is a continuation and claims the
benefit under 35 U.S.C. .sctn.120, of U.S. patent application Ser.
No. 12/533,963, filed Jul. 31, 2009, which claims priority to under
35 U.S.C. .sctn.120, of U.S. patent application Ser. No.
12/202,134, filed Aug. 29, 2008, now issued as U.S. Pat. No.
8,190,271, which claims priority under 35 U.S.C. .sctn.119(e) to
U.S. Provisional Patent Application No. 60/968,785, filed on Aug.
29, 2007. These applications are herein incorporated by reference
in their entireties.
BACKGROUND
[0002] A cochlear implant is a surgically implanted electronic
device that resides in the cochlea of a patient's ear and provides
a sense of sound to the patient who is profoundly deaf or severely
hard of hearing. The present specification relates to such neural
stimulators and, particularly, to cochlear implant systems that
include electrode arrays for stimulation of a patient's cochlea. In
a typical cochlear implant, an array of electrode contacts are
placed along one side of an elongate carrier or lead so that when
the array is implanted within one of the cochlear ducts, such as
the scala tympani, the electrode contacts are positioned in close
proximity to the cells that are to be stimulated. This allows such
cells to be stimulated with minimal power consumption.
[0003] To maximize the benefit of the surgery for the patient, it
is important to preserve the residual hearing of the patient and to
maximize the long term effectiveness of the cochlear implant. As
the cochlear lead is inserted through the tissues in the head and
into the cochlea, there can be mechanical damage to the surrounding
tissues, subsequent inflammation, and possibly damage to the
delicate structures within the cochlea. Additionally, various
autoimmune reactions can occur in response to the presence of the
cochlear lead in the cochlea. These autoimmune reactions can
include growth of tissue around the cochlear implant and eventual
ossification. This tissue growth can act as a barrier between the
electrodes of the cochlear implant and the target nerves. This can
lead to a degradation of the performance of the cochlear implant
over time.
BRIEF DESCRIPTION OF THE DRAWINGS
[0004] The accompanying drawings illustrate various embodiments of
the principles described herein and are a part of the
specification. The illustrated embodiments are merely examples and
do not limit the scope of the claims.
[0005] FIG. 1 is an illustrative diagram showing a cochlear implant
system in use, according to one embodiment of principles described
herein.
[0006] FIG. 2 is a diagram showing external components of an
illustrative cochlear implant system, according to one embodiment
of principles described herein.
[0007] FIG. 3 is a diagram showing the internal components of an
illustrative cochlear implant system, according to one embodiment
of principles described herein.
[0008] FIG. 4 is an illustrative cross-sectional diagram of the
cochlea showing the insertion location of the intra cochlear lead,
according to one embodiment of principles described herein.
[0009] FIG. 5 is an illustrative diagram of the insertion of the
terminal portion of an intra cochlear lead into the cochlea,
according to one embodiment of principles described herein.
[0010] FIG. 6 an illustrative diagram of representative
coefficients of friction for various coatings commonly used on
surgical devices, according to one embodiment of principles
described herein.
[0011] FIG. 7 is an illustrative diagram illustrating a series of
chemical reactions of silanes with silicone, according to one
embodiment of the principles described herein.
[0012] FIG. 8 is an illustrative chart showing the release of a
steroid from a polymer coating, according to one embodiment of
principles described herein.
[0013] FIG. 9 is a graph which illustrates the effectiveness of
dexamethasone base (DXMb) steroid in minimizing surgery induced
hearing loss, according to one embodiment of principles described
herein.
[0014] FIG. 10 is a graph which illustrates the effectiveness of
DXMb steroid in minimizing surgery induced hearing loss, according
to one embodiment of principles described herein.
[0015] FIG. 11 shows the efficacy of DXMb protecting the auditory
hair cells from electrode insertion trauma, according to one
embodiment of principles described herein.
[0016] FIG. 12 a cross-sectional diagram of one illustrative
cochlear lead with various coatings, according to one embodiment of
principles described herein.
[0017] FIG. 13 an illustrative graph of drug dose and release
kinetics, according to one embodiment of principles described
herein.
[0018] FIGS. 14A-14C are cross-sectional diagrams of an
illustrative cochlear lead with various coatings, according to one
embodiment of principles described herein.
[0019] FIG. 15 a cross-sectional diagram of an illustrative
cochlear lead with a cavity containing DXMb, according to one
embodiment of principles described herein.
[0020] FIG. 16 a longitudinal section of an illustrative cochlear
lead with a longitudinal lumen configured to accept various drug
compounds, according to one embodiment of principles described
herein.
[0021] FIG. 17 a cross-sectional diagram of illustrative cochlear
lead with a longitudinal lumen configured to accept various drug
compounds, according to one embodiment of principles described
herein.
[0022] FIGS. 18A and 18B are a top view and a cross-sectional
diagram, respectively, of illustrative dispensing mechanism for
pharmaceutical agents, according to one embodiment of principles
described herein.
[0023] FIG. 19 a cross-sectional diagram of illustrative cochlear
lead with an illustrative dispensing mechanism for pharmaceutical
agents, according to one embodiment of principles described
herein.
[0024] FIG. 20 is a top view of an illustrative cochlear lead with
an illustrative dispensing mechanism for pharmaceutical agents,
according to one embodiment of principles described herein.
[0025] FIG. 21 is a perspective view of an illustrative drug
releasing capsule and cochlear lead adapted to receive the capsule,
according to one embodiment of principles described herein.
[0026] Throughout the drawings, identical reference numbers
designate similar, but not necessarily identical, elements.
DETAILED DESCRIPTION
[0027] To place a cochlear implant, the terminal portion of a
cochlear lead is pushed through an opening into the cochlea. The
terminal portion of the lead is typically constructed out of
biocompatible silicone. This gives the terminal portion of the lead
the flexibility to curve around the helical interior of the
cochlea. However, silicone has a high coefficient of friction and
requires that a relatively high axial force be applied along the
cochlear lead during the insertion process. As a result, the
silicone can mechanically abrade or otherwise damage the interior
of the cochlea, which can cause inflammation and disturbance of the
vestibular duct or other structures, leading to nerve damage,
vertigo, and/or tinnitus. Additionally, autoimmune reactions can
cause nerve damage and undesirable tissue growth within the
cochlea. This can result in the encapsulation of the cochlear lead
by a layer of fibrotic tissue, which insulates the cochlear lead
from the remaining nerve cells and further reduces the
effectiveness of applied voltages.
[0028] As a consequence of this potential for damage to the
residual hearing of a patient and reduction of efficiency of the
cochlear lead over time, the majority of patients who are
considered for cochlear implants have severe or total hearing loss.
For this of group patients, the benefits provided by the cochlear
implant can outweigh the risk of residual hearing loss. However, by
solving the problems described above, cochlear implants could
improve the hearing and quality of life of a much broader range of
patients. Particularly, as a surgeon's ability to conserve residual
hearing increases, the potential to implant patients with greater
levels of baseline hearing can become a reality.
[0029] The initial mechanical tissue damage caused during the
insertion of the cochlear lead can be significantly reduced by
minimizing the coefficient of friction between the silicone and the
body tissues. The coefficient of friction can be minimized by
applying a lubricant to the outer surface of the silicone cochlear
lead. However, the outer surface of the silicone is smooth and
hydrophobic, which prevents the uniform and permanent application
of a biocompatible lubricant. This issue can be addressed by
altering the chemical characteristics of the exterior of the
silicone. Then, a variety of lubricants can be coated onto the
lead.
[0030] In addition to the need to reduce the mechanical damage
caused by the insertion of the cochlear lead, the administration of
various therapeutic drugs within the cochlea can minimize the
biological reactions to the surgery and presence of a foreign body.
The natural inflammation and immune system responses to the
insertion of the cochlear lead can be reduced by the proper
application of drugs intended to counter thrombus, fibrosis,
inflammation, and other negative reactions. Additionally, other
drugs could be applied to prevent infection, encourage the growth
or regeneration of nerve cells, or other desirable effects.
Ideally, a comparatively large dose of steroid or other appropriate
drug or drug combination would be administered during or shortly
after implantation of the cochlear lead. Following this initial
dose, a lower, long-duration dose could be administered to prevent
or reduce undesirable autoimmune system responses.
[0031] In the following description, for purposes of explanation,
numerous specific details are set forth in order to provide a
thorough understanding of the present systems and methods. It will
be apparent, however, to one skilled in the art that the present
systems and methods may be practiced without these specific
details. Reference in the specification to "an embodiment," "an
example," or similar language means that a particular feature,
structure, or characteristic described in connection with the
embodiment or example is included in at least that one embodiment,
but not necessarily in other embodiments. The various instances of
the phrase "in one embodiment" or similar phrases in various places
in the specification are not necessarily all referring to the same
embodiment.
[0032] Electrical stimulation of predetermined locations within the
cochlea of the human ear through an intracochlear electrode array
is described, e.g., in U.S. Pat. No. 4,400,590 (the "590 patent"),
which is incorporated herein by reference. The electrode array
shown in the '590 patent comprises a plurality of exposed electrode
pairs spaced along and imbedded in a resilient curved base for
implantation in accordance with a method of surgical implantation,
e.g., as described in U.S. Pat. No. 3,751,605, which is
incorporated herein by reference. The system described in the '590
patent receives audio signals, i.e., sound waves, at a signal
processor (or speech processor) located outside the body of a
hearing impaired patient. The speech processor converts the
received audio signals into modulated radio frequency (RF) data
signals that are transmitted through the patient's skin and then by
a cable connection to an implanted multi-channel intracochlear
electrode array. The modulated RF signals are demodulated into
analog signals and are applied to selected contacts of the
plurality of exposed electrode pairs in the intracochlear electrode
so as to electrically stimulate predetermined locations of the
auditory nerve within the cochlea.
[0033] U.S. Pat. No. 5,938,691, incorporated herein by reference,
shows an improved multi-channel cochlear stimulation system
employing an implanted cochlear stimulator (ICS) and an externally
wearable speech processor (SP). The speech processor employs a
headpiece that is placed adjacent to the ear of the patient, which
receives audio signals and transmits the audio signals back to the
speech processor. The speech processor receives and processes the
audio signals and generates data indicative of the audio signals
for transcutaneous transmission to the implantable cochlear
stimulator. The implantable cochlear stimulator receives the
transmission from the speech processor and applies stimulation
signals to a plurality of cochlea stimulating channels, each having
a pair of electrodes in an electrode array associated therewith.
Each of the cochlea stimulating channels uses a capacitor to couple
the electrodes of the electrode array.
[0034] Over the past several years, a consensus has generally
emerged that the scala tympani, one of the three parallel ducts
that make up the spiral-shaped cochlea, provides the best location
for implantation of an electrode array used as part of a cochlear
prosthesis. The electrode array to be implanted in the scala
tympani typically consists of a thin, elongated, flexible carrier
containing several longitudinally disposed and separately connected
stimulating electrode contacts, conventionally numbering about 6 to
30. Such an electrode array is pushed into the scala tympani duct
in the cochlea to a depth of about 20-30 mm via a cochleostomy or
via a surgical opening made in the round window at the basal end of
the duct.
[0035] In use, the cochlear electrode array delivers electrical
current into the fluids and tissues immediately surrounding the
individual electrode contacts to create transient potential
gradients that, if sufficiently strong, cause the nearby auditory
nerve fibers to generate action potentials. The auditory nerve
fibers branch from cell bodies located in the spiral ganglion,
which lies in the modiolus, adjacent to the inside wall of the
scala tympani.
[0036] Other patents relevant to the subject matter of cochlear
stimulation leads are: U.S. Pat. Nos. 6,125,302; 6,070,105;
6,038,484; 6,144,883; and 6,119,044, which are all herein
incorporated by reference. Other improved features of cochlear
implant systems are taught, e.g., in U.S. Pat. Nos. 6,129,753;
5,626,629; 6,067,474; 6,157,861; 6,249,704; and 6,289,247, each of
which is incorporated herein by reference.
[0037] While the electrode arrays taught in the above-referenced
patents are based on the correct goal, i.e., to force the electrode
carrier into a dose hugging engagement with the modiolus, they do
so only by using an additional element that makes manufacture of
the lead more difficult and expensive and only by applying an
additional pushing force to an electrode structure after it has
already been inserted into the cochlea. Such additional pushing
force may cause damage to the delicate scala tympani or cause the
electrode contacts to twist or to separate away from the modiolus,
rather than be placed in the desired hugging relationship. Thus,
while it has long been known that an enhanced performance of a
cochlear electrode or lead can be achieved by proper placement of
the electrode contacts dose to the modiolar wall of the cochlea, a
major challenge has been obtaining an electrode/lead design that
does not require excessive force to achieve this dose placement.
According to one illustrative embodiment, the surface of the
cochlear lead is modified to allow a lubricant to uniformly cover
the cochlear lead and minimize the insertion forces and resulting
trauma.
[0038] Additionally, the cochlear implant can be used as a vehicle
for carrying therapeutic substances, such as steroids and
antibacterial drugs, directly to disturbed tissues within the
cochlea. A variety of delivery mechanisms can be used to deliver
the drug or combination of drugs. A number of patents relate to
manufacturing methods and drug delivery by implantable leads,
including: U.S. Pat. Nos. 4,506,680 (a drug impregnated silicone
plug retained within a cavity in an implantable lead); 5,092,332 (a
drug impregnated polymeric layer bonded to an implantable lead);
5,103,837 (an implantable lead with a porous outer surface that
contains an anti-inflammatory steroid), 5,609,029 (a cochlear
implant with a drug impregnated outer coating); 5,496,360 (an
implantable lead having a central cavity configured to receive
various drug products); 5,824,049 (a manufacturing method for
applying a drug layer covered by porous layer of biocompatible
polymer to an implantable lead); 5,987,746 (an implantable lead
being coated with a drug which is no more than sparingly soluble in
water); 6,259,951 (an implantable cochlear lead which uses both
electrode and displacement stimulation); 6,304,787 (a cochlear lead
treated with a drug compound); 6,862,805 (a manufacturing method
for a cochlear implant); 6,879,695 (a personal audio system with an
implanted wireless receiver/audio transducer); 7,187,981 (an
implantable lead with a lubrication/drug eluting coating);
7,294,345 (a generic method for biological delivery of drug
compounds into a matrix); and 7,363,091 (an implantable lead
containing a silicone elastomer matrix containing steroids); U.S.
App. Nos.: 20070213799 (cochlear electrode arrays with drug eluting
portions); 20060282123 (medical devices resistant to tissue
overgrowth); 20060287689 (cochlear implants configured for drug
delivery); and 20080014244 (polymer matrix for containing
therapeutic drugs); European Pat. No.: EP0747069 (a manufacturing
method for applying a drug layer covered by porous layer of
biocompatible polymer to an implantable lead); PCT Publication Nos.
WO2008/024511 (layered matrix impregnated with therapeutic drugs)
and WO2008/014234 (a cochlear implant with a drug eluting polymer
material); which are all herein incorporated by reference. These
patents describe a number of manufacturing techniques which can be
utilized in conjunction various illustrative embodiments of
cochlear implants which are described below.
[0039] According to one illustrative embodiment, the drugs may be
coated on the outer surface of the implant, with the thickness and
surface area of the various layers corresponding to the desired
delivery drug profile and dose. In another embodiment, the drugs
may also be encapsulated in a matrix which gradually releases the
drugs into the intracochlear space. This matrix may be attached to
cochlear lead in a variety of ways, including as a coating, a plug,
or other geometry. In another illustrative embodiment, the drugs
could also be delivered as a powder that is contained within a
cavity of the implant. The drug type, particle size, cavity
opening, covering membrane or other means could be used to control
the delivery of the drug. However, in all cases, the amount of drug
delivered is constrained by the need to minimize the size of the
intracochlear lead. Any increase in the size of the intracochlear
lead increases the potential for mechanical damage and disruption
to the cochlea. Thus, a selection of the most efficacious drug or
combination of drugs is important, given that only a small quantity
of the drugs can be delivered via the intracochlear lead.
[0040] As mentioned above, and by various incorporated references,
a variety of drugs or drug combinations could be beneficial for a
patient receiving a cochlear implant. In the past, one of the
primary considerations in selecting drugs for administration on
electrical nerve stimulation implants (such as vagus nerve
stimulators, pace makers, cochlear leads, etc.) was that the drugs
should have a high solubility in aqueous solutions. The majority of
the fluids within the human body contain a high percentage of
water, and thus serve as an aqueous solution capable of acting as a
solvent for the drugs. However, the applicants have discovered that
dexamethasone base (DXMb), which has a very low solubility in
aqueous solutions, was surprisingly efficacious when administered
into the intracochlear space after implantation surgeries.
Additionally, DXMb was surprisingly more potent than salt forms of
dexamethasone. This surprising potency allows for increased
therapeutic effects without increasing the volume of the drug or
the size of the intracochlear lead.
[0041] FIG. 1 is a diagram showing one illustrative embodiment of a
cochlear implant system (100) having a cochlear implant (300) with
an electrode array that is surgically placed within the patient's
auditory system. Ordinarily, sound enters the external ear, or
pinna, (110) and is directed into the auditory canal (120) where
the sound wave vibrates the tympanic membrane (130). The motion of
the tympanic membrane is amplified and transmitted through the
ossicular chain (140), which consists of three bones in the middle
ear. The third bone of the ossicular chain (140), the stirrup
(145), contacts the outer surface of the cochlea (150) and causes
movement of the fluid within the cochlea. Cochlear hair cells
respond to the fluid-borne vibration in the cochlea (150) and
trigger neural electrical signals that are conducted from the
cochlea to the auditory cortex by the auditory nerve (160).
[0042] As indicated above, the cochlear implant (300) is a
surgically implanted electronic device that provides a sense of
sound to a person who is profoundly deaf or severely hard of
hearing. In many cases, deafness is caused by the absence or
destruction of the hair cells in the cochlea, i.e., sensorineural
hearing loss. In the absence of properly functioning hair cells,
there is no way auditory nerve impulses can be directly generated
from ambient sound. Thus, conventional hearing aids, which amplify
external sound waves, provide no benefit to persons suffering from
complete sensorineural hearing loss.
[0043] Unlike hearing aids, the cochlear implant (300) does not
amplify sound, but works by directly stimulating any functioning
auditory nerve cells inside the cochlea (150) with electrical
impulses representing the ambient acoustic sound. Cochlear
prosthesis typically involves the implantation of electrodes into
the cochlea. The cochlear implant operates by direct electrical
stimulation of the auditory nerve cells, bypassing the defective
cochlear hair cells that normally transduce acoustic energy into
electrical energy.
[0044] External components (200) of the cochlear implant system can
include a Behind-The-Ear (BTE) unit (175), which contains the sound
processor and has a microphone (170), a cable (177), and a
transmitter (180). The microphone (170) picks up sound from the
environment and converts it into electrical impulses. The sound
processor within the BTE unit (175) selectively filters and
manipulates the electrical impulses and sends the processed
electrical signals through the cable (177) to the transmitter
(180). The transmitter (180) receives the processed electrical
signals from the processor and transmits them to the implanted
antenna (187) by electromagnetic transmission. In some cochlear
implant systems, the transmitter (180) is held in place by magnetic
interaction with the underlying antenna (187).
[0045] The components of the cochlear implant (300) include an
internal processor (185), an antenna (187), and a cochlear lead
(190) having an electrode array (195). The internal processor (185)
and antenna (187) are secured beneath the user's skin, typically
above and behind the pinna (110). The antenna (187) receives
signals and power from the transmitter (180). The internal
processor (185) receives these signals and performs one or more
operations on the signals to generate modified signals. These
modified signals are then sent through the cochlear lead (190) to
the electrode array (195). The electrode array (195) is implanted
within the cochlea (150) and provides electrical stimulation to the
auditory nerve (160).
[0046] The cochlear implant (300) stimulates different portions of
the cochlea (150) according to the frequencies detected by the
microphone (170), just as a normal functioning ear would experience
stimulation at different portions of the cochlea depending on the
frequency of sound vibrating the liquid within the cochlea (150).
This allows the brain to interpret the frequency of the sound as if
the hair cells of the basilar membrane were functioning
properly.
[0047] FIG. 2 is an illustrative diagram showing a more detailed
view of the external components (200) of one embodiment of a
cochlear implant system. External components (200) of the cochlear
implant system include a BTE unit (175), which comprises a
microphone (170), an ear hook (210), a sound processor (220), and a
battery (230), which may be rechargeable. The microphone (170)
picks up sound from the environment and converts it into electrical
impulses. The sound processor (220) selectively filters and
manipulates the electrical impulses and sends the processed
electrical signals through a cable (177) to the transmitter (180).
A number of controls (240, 245) adjust the operation of the
processor (220). These controls may include a volume switch (240)
and program selection switch (245). The transmitter (180) receives
the processed electrical signals from the processor (220) and
transmits these electrical signals and power from the battery (230)
to the cochlear implant by electromagnetic transmission.
[0048] FIG. 3 is an illustrative diagram showing one embodiment of
a cochlear implant (300), including an internal processor (185), an
antenna (187), and a cochlear lead (190) having an electrode array
(195). The cochlear implant (300) is surgically implanted such that
the electrode array (195) is internal to the cochlea, as shown in
FIG. 1. The internal processor (185) and antenna (187) are secured
beneath the user's skin, typically above and behind the pinna
(110), with the cochlear lead (190) connecting the internal
processor (185) to the electrode array (195) within the cochlea. As
discussed above, the antenna (187) receives signals from the
transmitter (180) and sends the signals to the internal processor
(185). The internal processor (185) modifies the signals and passes
them through the cochlear lead (190) to the electrode array (195).
The electrode array (195) is inserted into the cochlea and provides
electrical stimulation to the auditory nerve. This provides the
user with sensory input that is a representation of external sound
waves sensed by the microphone (170).
[0049] FIG. 4 shows a cross sectional diagram of the cochlea (150)
taken along line 4-4 in FIG. 1. The walls of the hollow cochlea
(150) are made of bone, with a thin, delicate lining of epithelial
tissue. The primary structure of the cochlea is a hollow tube that
is helically coiled, similar to a snail shell. The coiled tube is
divided through most of its length by the basilar membrane (445).
Two fluid-filled spaces (scalae) are formed by this dividing
membrane (445). The scala vestibuli (410) lies superior to the
cochlear duct. The scala tympani (420) lies inferior to the scala
cochlear duct. The scala media (430) is partitioned from the scala
vestibuli (410) by Reissner's membrane (440).
[0050] The cochlea (150) is filled with a watery liquid, which
moves in response to the vibrations coming from the middle ear via
the stirrup (145). As the fluid moves, thousands of "hair cells"
(445) in a normal, functioning cochlea are set in motion and
convert that motion to electrical signals that are communicated via
neurotransmitters to many thousands of nerve cells (400). These
primary auditory neurons (400) transform the signals into
electrical impulses known as action potentials, which travel along
the auditory nerve to structures in the brainstem for further
processing. The terminal end of the cochlear lead (190) is inserted
into the scala tympani with the electrodes (195) preferably being
positioned in close proximity to the nerve (400).
[0051] As shown in FIG. 5, the tip of the cochlear lead (190) is
inserted through an incision in the cochlea (150) and pushed into
the scale tympani (420) so that the tip of the lead conforms to the
helical shape of the scala tympani. A major problem with electrode
insertion is potential damage to the delicate structures within the
cochlea. To insert the cochlear lead, a passageway is made through
the body tissues of the head to expose the cochlea. The tip of the
electrode is inserted through an opening in the cochlea. The
electrode is then pushed axially into the cochlea. The force of the
tip against the inner wall of the cochlear channel bends the
flexible tip. When the tip is in its final position, the electrode
array is entirely contained within the cochlea and the individual
electrodes (195) are placed proximate the nerve cells (400). When
electrical current is routed into an intracochlear electrode (195),
an electric field is generated and the auditory nerve fibers (400,
FIG. 4) are selectively stimulated.
[0052] Many surgeons, in an off-label practice, apply a lubricant
HEALON (Pharmacia Corporation, Peapack, N.J., USA) to the electrode
array to decrease the friction between the cochlear implant lead
and the patient's internal tissues. However, HEALON lubricant is
highly viscous and when applied at the time of surgery, there is
little or no control over the conformity of the coating across the
silicone surface.
[0053] According to one illustrative embodiment, a pre-coated
cochlear lead can be used to ensure the desired amount of surface
area is coated with a uniform and reliable lubricant. Increasing
lubricity of the silicone in the cochlear implant lead will help to
reduce the probability that the soft tissues of the cochlear will
be torn upon electrode insertion and make the insertion of leads
much easier.
[0054] FIG. 6 shows experimental results of tests performed with
various materials that are used as the outer surfaces of medical
devices. The vertical axis shows the range of the coefficient of
friction. The horizontal axis shows various materials that were
tested. For example, uncoated silicone cardiac rhythm management
(CRM) leads had a coefficient of friction of approximately 1. After
a hydrophilic lubricious coating was applied to the silicone, the
coefficient of friction was reduced to approximately 0.1. Thus, the
use of a lubricious coating may reduce friction forces by 90% or
more as shown in FIG. 6 on various surfaces, including silicone as
used in the cochlear lead's electrode array.
[0055] Silicone is known to be an unreactive polymer. It has a very
low surface energy and is wettable by few liquids. Therefore, it is
difficult to attach molecules or coatings to its surfaces. Its
surfaces can be made wettable and hydrophilic by subjecting the
silicone to oxygen plasma. This introduces hydroxyl groups on the
exposed silicone surfaces. However, these wetting and hydrophilic
properties are temporary. Silicone undergoes rapid surface
inversion and reverts back to a hydrophobic and unwettable material
within 24 hours.
[0056] However, within the time immediately after treatment of the
silicone with oxygen plasma, these temporary hydroxyl groups may be
utilized to attach coatings or to derivatize the surface. Examples
of reactive molecules that could be used to modify the surface
include Propyltrimethoxysilane
(C.sub.3H.sub.7--Si(OCH.sub.3).sub.3),
Glycidoxypropyltrimethoxysilane
(CH.sub.2(O)CHCH.sub.2OC.sub.3H.sub.6--Si(OCH.sub.3).sub.3),
Aminopropyltriethoxysilane
(H.sub.2C.sub.3H.sub.6--Si(OC.sub.2H.sub.5).sub.3),
Aminoethylaminopropyltrimethoxysilane
(H.sub.2NC.sub.2H.sub.4NHC.sub.3H.sub.6--Si(OCH.sub.3).sub.3),
Methacryloxypropyltrimethoxysilane
(H.sub.2C.dbd.CH(CH.sub.3)C(O)OC.sub.3H.sub.6--Si(OCH.sub.3).sub.3),
Mercaptopropyltrimethoxysilane (HS(CH.sub.2).sub.3Si(OMe).sub.3),
Chloropropyltrimethoxysilane (CIC.sub.3H.sub.6--Si(OCH.sub.3)),
Phenyltriethoxysilane (C.sub.6H.sub.5--Si(OCH.sub.3).sub.3) and
Vinyltrimethoxysilane (H.sub.2C.dbd.CH--Si(OCH.sub.3).sub.3). All
of these compounds can react permanently with the hydroxyl groups
through a covalent linkage via a silyl ether linkage. These alkoxy
silanes have been added to lattices and hydrolyzed to form an
interpenetrating polymer network (IPN) polymer with improved
properties.
[0057] Two types of alkoxy silanes have widespread application in
the coatings industries: alkyl/aryl and organofunctional.
Possessing both organic and inorganic properties, these hybrid
chemicals react with the polymer, forming durable covalent bonds
across the interface. It has been proposed that these bonds are
hydrolyzable, but can reform, and therefore provide a means of
stress relaxation at the organic/inorganic interface. The results
are improved adhesion and durability.
[0058] FIG. 7 shows a diagram of the reaction of silanes to enhance
bonding with a substrate. Initially, hydrolysis of the alkoxy
groups occurs. It is after the first and second alkoxy groups are
hydrolyzed that condensation to oligomers follows. The tendency
toward self condensation can be controlled by using fresh
solutions, alcoholic solvents, dilution, and by careful selection
of pH ranges. The third methoxy group upon hydrolysis is oriented
towards and hydrogen bonds with the hydroxyl groups on the silicone
surface. Finally, during curing (110.degree. C./10 min) a covalent
bond is formed with the silicone, water is liberated and the
interpenetrating network is formed improving the mechanical
strength and preventing surface inversion of the silicone.
[0059] The most straightforward method of silylating a surface with
a silane is from an alcohol solution. A two percent silane solution
can be prepared in the alcohol of choice (methanol, ethanol, and
isopropanol are typical choices). The solution can be wiped,
dipped, or sprayed onto the surface. After the surface dries,
excess material can be gently wiped, or briefly (alcohol) rinsed
off. Cure of the silane layer is for 5-10 minutes at 110.degree. C.
or for 24 hours at ambient conditions.
[0060] The resulting additives change the surface energy of the
silicone polymer (e.g., more lubricious and wettable) and makes the
silicone surface much more reactive for subsequent reactions. For
example, if the silicone were treated with
Methacryloxypropyltrimethoxysilane,
H.sub.2C.dbd.CH(CH.sub.3)C(O)OC.sub.3H.sub.6--Si(OCH.sub.3).sub.3,
it would have a free vinyl group which could subsequently be used
to react with a hydrophilic vinyl containing monomer, oligomer, or
polymer, forming a covalent bond by free radical reaction. This
hydrophilic coating would render the silicone not only lubricious
but also able to imbibe drugs for subsequent drug delivery.
[0061] As described above, one method of precisely delivering the
steroid is to impregnate the chemically modified silicone of the
cochlear implant lead with the steroid. The steroid leaches out of
the porous silicone over time, creating a time release mechanism
for delivering the steroid directly the tissue affected by the
implantation of the lead.
[0062] FIG. 8 shows the drug elution of a steroid DEX salt from the
polystyrene-polyisobutylene-polystyrene (SIBS) polymer coating.
SIBS is an elastomeric block copolymer of polystyrene and
polyisobutylene used for medical applications such as stent
coatings. The vertical axis shows the total amount of DEX salt
released in micrograms. The horizontal axis shows elapsed time in
days. The test shows the advantageous release of large quantities
of steroid immediately following the insertion of the surgical
device. As the tissues heal over a period of time, the need for
steroid intervention decreases. The elution profiles shown in FIG.
8 show a corresponding reduction in the rate of steroid elution
over a period of days. The elution profile can be chosen to match
the needs of the patient by increasing or decrease the percentage
of DEX salt in the SIBS polymer.
[0063] In one alternative embodiment, the steroid is delivered in
combination with lubrication. A lubricant containing a steroid
substance is applied along the length in part or in whole to the
cochlear lead to minimize trauma to the cochlea. The lubricant will
allow the lead to be more easily inserted by reducing frictional
forces that can tear soft tissues. During insertion and post
insertion of the lead, the steroid substance will diffuse into the
surrounding tissues and reduce the initial trauma and subsequent
inflammation that the cochlea and other tissues may experience.
Minimizing inflammatory processes during and after the insertion of
the cochlear lead can increase the probability of preserving
residual hearing.
[0064] A class of lubricants referred to as "slippery when wet"
lubricants have the characteristic of being applied, packaged, and
transported as a dry powder or dry coating. Prior to insertion, the
coated article is immersed or otherwise brought into contact with
an aqueous solution (typically purified water or saline solution).
The dry powder absorbs the solution and becomes lubricious. As the
coated object is inserted into tissue, it further absorbs body
fluids to enhance its low friction characteristics.
[0065] In embodiments using "slippery when wet" lubricants where
the steroid is to be combined with the lubricant, the "slippery
when wet" lubricant powder or dry coating is brought into contact
with a steroid solution. The lubricant coating absorbs the steroid
and delivers it to tissues that the coated object encounters. The
steroid could also be coated directly on the silicone as part of
the lubricious coating. The lubricious coating consists of one- or
multiple-layer polymer coatings bound to the silicone. In the case
that multiple coatings are used, the base coating may provide
excellent adhesion to the silicone substrate while also containing
the steroid. The top coating may provide the improved lubricity to
ease the surgical implantation of the cochlear implant lead.
[0066] In these exemplary embodiments, a variety of commercially
available lubricious coatings could be used. By way of example and
not limitation, the following lubricants could be used: LUBRILAST
from AST Products, HARMONY from SurModics, SILGLIDE from Applied
Membrane Technology, HYDAK from Biocoat, F2 series from Hydromer,
and others.
[0067] The lubricious coating can be applied to the lead using any
of a number of techniques. For example, the lubricious coating can
be applied by means of dip coating, spray coating,
electro-deposition, direct printing (such as with ink-jet
technology) or brush painting.
[0068] In another exemplary embodiment, the steroid could be
encased in a vesicle, such as a nanoparticle or liposome vesicle,
or combined with a biodegradable substance to facilitate time
release. Nanoparticles and liposomes could be suspended in the
lubricious coating or contained within porous coatings. In addition
to the benefits described above, the polymer coating on cochlear
leads may provide additional valuable characteristics such as
anti-microbial, anti-thrombogenic and reduced fibrosis.
[0069] Alternative lubricants include a hydrophilic polymeric
material such as plant- and animal derived natural water-soluble
polymers, semi-synthetic water-soluble polymers, and synthetic
water-soluble polymers. Further, the water-soluble polymers are can
be stabilized (turned to be water-insoluble) by such means as
crosslinking. Specific examples of the hydrophilic polymeric
material include polyvinyl pyrrolidone (PVP), acrylic acid-based
polymers, polyvinyl alcohols, polyethylene glycol, cellulose
derivatives such as cellulose, methyl cellulose, and hydroxypropyl
cellulose; sugars such as mannan, chitosan, guar gum, xanthan gum,
gum arabic, glucose, and sucrose; amino acids and the derivatives
thereof such as glycine, serine, and gelatin; and natural polymers
such as polylactic acid, sodium alginate, and casein. In this
embodiment, PVP or an acrylic acid-based polymer can be used, in
view of excellent compatibility with the underlying lead and
excellent operability at the time of inserting or withdrawing the
lead.
[0070] As described herein, concerns are raised by the tissue
damage done when a cochlear lead is implanted. Additionally, in
some patients, the presence of the implant activates the patient's
immune response resulting in a rejection of the implant. To address
these issues, a steroid substance applied to surgically disrupted
tissues can improve patient outcomes. The advantages of locally
delivered drugs include increased local and decreased systemic drug
concentration thereby lessening the potential for serious side
effects. As described above, steroids, such as Dexamethasone (DEX),
can help control inflammation and autoimmune responses.
Dexamethasone is a potent synthetic member of the glucocorticoid
class of steroid hormones. Dexamethosone demonstrates
glucocorticoid (suppressing allergic, inflammatory, and autoimmune
reactions) effects and serves as an antiphlogistic
(anti-inflammatory) agent. Its potency is about 20-30 times that of
hydrocortisone and 4-5 times that of prednisone.
[0071] When dexamethasone or its derivatives are mentioned in
literature, it is invariably a reference to a dexamethasone salt.
Dexamethasone salts, such as dexamethasone sodium phosphate,
dexamethasone acetate, dexamethasone sulfate, dexamethasone
isonicontinate, etc., are used because the water solubility of the
salts forms of dexamethasone are much greater than the base form.
Consequently, the salt forms were thought to be more easily
delivered to living tissues and appear to be used exclusively in
the prior art.
[0072] However, the inventors discovered that dexamethasone base
(DXMb), which has a very low solubility in aqueous solutions, was
surprisingly efficacious when administered into the intracochlear
space after implantation surgeries. Additionally, DXMb was
surprisingly more potent than salt forms of dexamethasone. In one
study performed by the Applicants, a comparison of DXMb and DEX
salt was performed in an in-vivo model over the prior of a week.
The Applicants found that DXMb delivered at 1 .mu.L/hr at a
concentration of 70 .mu.L/ml (limit of DXMb solubility in aq
solution) was just as effective DEX salt delivered at a
concentration of 100 .mu.L/ml at 1 .mu.L/hr. This surprising
potency allows for increased therapeutic effects without increasing
the volume of the drug or the size of the intracochlear lead.
[0073] The efficacy of DXMb was also studied by the Applicants in
relationship to preserving residual hearing and internal nerve
structures within the cochlea. In the study performed by the
Applicants, 88 ears of 44 pigmented guinea pigs of 250 to 300 grams
were randomly assigned to one of four groups as follows: group 1
corresponded to the contralateral, unoperated ears from groups 2 to
4 animals (n=44). Group 2 (n=15): electrode insertion trauma (EIT);
these ears underwent EIT only via a cochleostomy and then immediate
closure. Group 3 (n=15): EIT+artificial perilymph (EIT+AP) treated
ears received EIT and immediately after trauma, insertion of a
microcatheter into the cochleostomy site with AP perfused into the
scale tympani (ST) for a period of 8 days. Group 4 (n=14): EIT
dexamethasone base (EIT=DXMb) treated animals underwent EIT
followed immediately by insertion of a microcatheter into the
cochleostomy with ST perfusion of DXMb (70 g/mL) in AP for a period
of 8 days. Hearing measurements were performed before surgery, as
well as on post-EIT days 0, 3, 7, 14, and 30. Tone bursts of 0.5,
1, 4, and 16 kHz were delivered to the ear at a rate of 29 Hz. The
intensity of the stimulation was decreased by 10 dB sound pressure
level (SPL) decrements until no auditory brainstem response was
identified.
[0074] FIG. 9 shows charts auditory functions of the various test
groups as a function of time. Each of the charts show box plots of
mean auditory brainstem response threshold values by time for a set
of low (0.5 kHz) frequency pure tone stimuli. A line passes through
mean value of each the temporal measurement. The ends of the boxes
are the 25th and 75th quartiles. The horizontal line across the
middle of the boxes identifies the median threshold values. The
whiskers at the ends of the boxes extend to the outermost data
points. (A) Represents values for the control ears (group 1, n=44),
(B) for group 2 (EIT, n=15), (C) for group 3 (EIT+AP, n=15), and
(D) for group 4 (EIT+DXMb, n=14).
[0075] Chart A in FIG. 9 shows that there is no change the hearing
capability in the control ears which have not been disturbed by
surgery. Chart B shows that there is significant hearing loss (the
measurements trend higher, showing that an increase tone volume is
required to detect an auditory brainstem response) for ears where
there was surgery performed but no treatment was provided.
Similarly, Chart C shows that there was a significant hearing loss
in ears where a placebo (artificial perilymph) was administered.
Chart D shows test results for ears where DXMb was administered. In
Chart D, there was a sharp increase in hearing loss immediately
following the surgery, but this hearing loss was reversed by the
administration of the DXMb. Over the long term, the administration
of DXMb maintained the pre-operative hearing levels.
[0076] FIG. 10 shows that DXMb treatment similarly conserves
auditory function thresholds at 16 kHz after electrode insertion
trauma. Chart A shows that there is no significant change the
hearing capability in the control ears which have not been
disturbed by surgery. Chart B shows that there is dramatic hearing
loss for ears where there was surgery performed but no treatment
was provided. Chart C shows that there was a less dramatic but
still significant hearing loss in ears where a placebo was
administered, Chart D shows test results for ears where DXMb was
administered. In Chart D, there was a sharp increase in hearing
loss immediately following the surgery, but this hearing loss was
reversed, and continued to decline as DXMb was administrated.
Consequently, it can be concluded that DXMb treatment can conserve
auditory function thresholds over a range of frequencies after
electrode insertion trauma.
[0077] FIG. 11 shows Organ of Corti photomicrographs from an area
of the lower middle turn of four representative cochleae thirty
days after electrode insertion trauma. The control specimen
(photomicrograph A) is the contralateral unoperated cochlea which
shows the undamaged structure of hair cells (arrow, "HCs"). The
organization of hair cells is in three distinct rows.
Microphotograph B shows an area of damaged hair cells (arrow,
"Damaged HCs") from the group which received no treatment following
electrode insertion trauma. Microphotograph C shows an area of
damaged hair cells (arrow, "Damaged HCs") from the group which
received a placebo treatment. However, microphotograph C shows that
there are fewer missing hair cells than shown in B. A possible
explanation for the better preservation of hair cells receiving the
placebo treatment (the cochlea was flushed with artificial
perilymph rather than DXMb) was that the flushing action reduced
the autoimmune actors in the intracochlear space. Microphotograph D
is a photograph of hair cells from a specimen that received DXMb
treatment following electrode insertion trauma. The hair cells and
hair cell structure of microphotograph D are substantially similar
to that of the control group, showing that DXMb treatment is
effective in reducing damage to intracochlear structures following
electrode insertion trauma.
[0078] As mentioned above, optimal delivery of a steroid as a means
of minimizing negative surgical side effects varies by situation,
but typically delivery directly to the disturbed tissues is
desired. For example, the base or salt form of Dexamethasone can be
combined with either or both of a surface lubricant or the
underlying silicone. The sodium salt form of dexamethasone is
highly soluble in aqueous preparations which allows for the
application of very high dose levels of this synthetic
corticosteroid if required. In contrast, the base variant of
dexamethasone (i.e., DXMb) is highly soluble in organic solvents
but has limited solubility in aqueous preparations. This difference
in solubility between the salt and base forms of dexamethasone can
be leveraged to provide a time varying release profile of steroid
into the intracochlear space. For example, a high dosage of steroid
is often found to beneficial during or immediately following the
surgery and implantation process. This high dosage of steroid or
other anti-inflammatory drug can mitigate swelling, nerve damage,
and aid in the post operative recovery of the patient. For a period
of time after the surgery, a lower level and sustained release of
steroid or other medication can be desirable to prevent immune
system rejection of the cochlear implant, ossification, tissue
build up within the cochlea, and progressive nerve damage.
[0079] The combination of DEX salt and DXMb can provide a time
varying release of steroids. According to one illustrative
embodiment, various layers of drugs could be applied to achieve the
desired release profile and combination of drugs. For example, an
outer layer could be composed of DEX salt and an inner layer could
be composed of DXMb. The outer layer of DEX salt would be rapidly
released during the implantation, while the inner layer of DEX salt
would be more slowly released for long term treatment. Other drugs
could be used in combination with DEX salts or DXMb to supply a
broader spectrum of benefits. By way of example and not limitation,
a heparin layer could be added as a thrombin inhibitor. The
layering sequence and compositions could also be used to control
the release rate of various drugs. For example, a heparin under
layer could be used to increase the release rate of an overlying
DEX salts or DXMb by about a factor of 10. The various layers could
be applied using a variety of techniques. By way of example and not
limitation, the layers could be applied by painting, spraying,
printing (similar to ink jet technology using large or very small
(picoliter) droplets), and/or dipping the lead until the desired
dose is applied.
[0080] In one illustrative embodiment, the DEX salt or DXMb could
be dissolved in a carrier fluid and applied to cochlear lead
surface. The carrier would then evaporate or otherwise be removed,
leaving the DEX salt or DXMb layer or layers in place on the
cochlear lead. A number of solvents could be used. For DEX salt
coatings, various aqueous solutions could be used. For DXMb
coatings, organic solvents could be used. By way of example and not
limitation, these organic solvents may include methanol, ethanol,
isopropanol, acetone, chloroform, and others. A variety of factors
could influence the choice of carrier solutions, including: the
solubility of DEX salt or DXMb in the chosen solution, the
evaporation rate of the carrier, the ease of applying and handling
the solution, the toxicity of any remaining carrier, the
compatibility of the carrier with the underlying substrates, and
other factors.
[0081] FIG. 12 is a cross-sectional diagram of a cochlear lead
(1200) that is coated with multiple drug eluting layers (1205,
1210). According to one illustrative embodiment, a first layer
(1210) containing DXMb is deposited on the outer surface of the
cochlear lead (1200). A second layer (1210) containing a DEX salt
is deposited over the first layer (1210). As discussed above, the
DEX salt highly soluble in water or solutions that contain a high
percentage of water. The intracochlear fluid is primarily water.
Consequently, the DEX salt is quickly dissolved by the
intracochlear fluid and rapidly attains a relatively high
concentration of DEX salt within the fluid. By configuring the
cochlear implant to make available a given amount of DEX salt from
the second layer (1210) during and immediately after implantation,
the desired burst of steroid can be administered. After the initial
release of DEX salt, the DXMb contained within the second layer
(1205) can provide lower levels of steroid within the cochlea for a
sustained period. The saturation concentration of DXMb within the
cochlear fluid is much lower than that of DEX salt, leading to a
slower release/dissolution of the DXMb into the cochlear fluid.
Additionally, as described above, it has been found that DXMb can
be more potent on a per mass basis than a DEX salt. This allows a
larger therapeutic dose of DXMb to be delivered within the size
constraints imposed by the cochlea and electrode geometries.
Although no concrete explanation for the higher potency is
provided, this could possibly be due to longer clearance times of
DXMb. A clearance time is measurement of the time during which a
drug remains within a portion of the body before it is transported
or otherwise removed from the body. The lower solubility of the
DXMb may lead to slower transport of the DXMb out of the
intracochlear region.
[0082] FIG. 13 shows a chart illustrating hypothetical drug dose
and release kinetics associated with a DEX salt/DXMb combination,
such as the geometry illustrated in FIG. 12. The horizontal axis of
the chart represents the passage of time after administration of
the DEX salt/DXMb combination. The vertical axis represents the
intracochlear drug concentrations. A dashed line (1300) illustrates
a hypothetical release profile for DEX salt. As shown by the dashed
line (1300), the DEX salt is rapidly dissolved by the intracochlear
fluid and, due to the high solubility of the DEX salt in the
intracochlear fluid, a high concentration of DEX salt rapidly
accumulates in the cochlea. This high concentration of DEX salt
mitigates the immediate damage caused by the electrode insertion.
The concentration of the DEX salt rapidly declines as the DEX salt
is consumed and/or transported out of the cochlea. The DXMb
concentrations are illustrated by a dot-dash line (1305). The DXMb
concentrations increase much more slowly and are sustained within
the intracochlear space for a longer period of time.
[0083] The DEX salt/DXMb combination could be combined with the
cochlear implant in a number of alternative methods. For example, a
cochlear implant could be coated with a hydrophilic layer. The
hydrophilic layer could be made up of a number of materials that
would absorb or retain an aqueous solution, such as a "slippery
when wet" lubricant or a hydrogel such as HYDROMER polyvinyl
pyrrolidone. A DEX salt or a combination of DEX salt and DXMb could
be dissolved in the solution. The aqueous solution could then be
used to load the hydrophilic layer with DEX salt or DXMb. In one
embodiment, the all or a portion of the cochlear implant could
packaged and shipped in the solution. In other embodiments, the
cochlear implant could be soaked in the DEX solution prior to use.
In one illustrative embodiment, the solution could include a
combination of aqueous and organic solvents to provide the desired
delivery of DEX salt and DXMb.
[0084] FIG. 14A shows an alternative embodiment of a cochlear lead
(1400) where a DXMb layer (1405) is applied to the cochlear lead
(1400), followed by a lubricant layer (1410). Prior to the
insertion of the cochlear lead (1400) into the body tissues, the
lead is submerged in an aqueous solution containing DEX salt
(1415). The aqueous solution (1415) is absorbed by the lubricant
layer (1410). This hydrates the lubricant and reduces the
coefficient of friction between the cochlear lead (1400) and the
surrounding tissues. Additionally, a portion of the DEX salt is
eluted out of the lubricant layer (1410) as the cochlear lead
passes through the tissues, thereby directly depositing the steroid
on the disturbed tissues. Further, because the DXMb layer (1405)
has only a low solubility in aqueous solutions, it will not
dissolve or lose its structural integrity during the hydration and
insertion process.
[0085] Another advantage of DXMb relates to its high solubility in
organic solvents. Organic solvents are used in a variety of
processes, including the preparation of polymers. By dissolving
DXMb in an organic solvent, DXMb can be easily incorporated into a
variety of biocompatible polymers. The DXMb can then be gradually
eluted from the polymer to produce the desired drug release
kinetics.
[0086] FIG. 14 B shows an illustrative embodiment of a cochlear
lead (1400) with a polymer coating (1420). According to one
illustrative embodiment, the polymer coating (1420) includes mixed
active agents which gradually are eluted polymer coating. For
example, the mixed active agents may include a combination of DXMb
and DEX salts. As discussed above, the ratio of DXMb and DEX salts
may be adjusted to achieve the desired release profile and
biological benefit. The polymer coating (1420) may be applied using
a variety of methods. By way of example and not limitation, the
polymer coating (1420) may be applied by dip coating, brush
coating, spray coating or other methods.
[0087] FIG. 14 C shows an illustrative embodiment of a cochlear
lead (1400) with an active layer (1430) which is covered by a
polymer coating (1435). According to one illustrative embodiment,
the active layer (1430) may include mixed active agents such as a
combination of DXMb and DEX salts. The polymer coating (1435) may
serve as a protecting layer which prevents the active layer (1430)
from damage. Additionally, the polymer coating (1435) may serve as
a membrane which moderates the release rate of drugs which are
eluted from the active layer (1430).
[0088] According to one illustrative embodiment, the polymer
coating (1435) may be hydrophobic or hydrophilic. Advantages of a
hydrophobic coating may include lower permeability to water
solutions, longer term dimensional stability, lower elution rates
of drugs from the underlying active layer. Advantages of a
hydrophilic coating may include higher elution rates of drugs from
the underlying active layer, greater lubricity, the ability to
absorb and carry water soluble solutions. According to one
illustrative embodiment, the polymer coating (1435) has a higher
lubricity than the underlying silicone surface of the cochlear lead
(1400).
[0089] FIG. 15 shows a cross-sectional diagram of a cochlear lead
(1500) with an electrode (1505) and a cavity (1520) which runs
along the length of the intracochlear lead (1500). The cavity
(1520) could have a variety of geometries as best suits the
situation. For example, the cross-sectional shape of the cavity
(1520) could be altered to best retain and dispense the drug or
drug combination contained within the cavity (1520). According to
one illustrative embodiment, the cavity (1520) is filled with a
matrix which contains DXMb (1510). As described, above DXMb can be
incorporated into a number of biocompatible polymers. This drug
loaded polymer can be shaped to fill a variety of cavity
geometries. According to one embodiment, the drug loaded polymer
may adhere to the cavity wall or be applied as a coating to the
cochlear lead surface.
[0090] In an alternative embodiment, powdered drugs or drug
combinations may be used to fill the cavity (1520). A selectively
permeable membrane (1515) may be used to cover the opening of the
cavity (1520) and retain the powder. When the cochlear implant is
inserted into tissue or the intracochlear space, body fluids pass
through the membrane and dissolve the drug particles, which then
pass through the membrane and into the surrounding tissues.
According to one exemplary embodiment, DXMb powder (1510) is used
to fill the tissue, and a membrane (1515) having a pore size of no
greater than 10 microns is used to retain the DXMb powder (1510).
According to one illustrative embodiment, the pore size is less
than 6 microns. In another illustrative embodiment, the pore size
is less than 0.2 microns. The membrane (1515) pore size is
configured to prevent the passage of bacteria across the membrane
but allows water and dissolved DXMb cross the membrane. Smaller
pore sizes may exclude a greater number of bacteria. In other
embodiments, the membrane may have pore sizes that range from
nanofeatures to very large macroscopic holes. In one illustrative
embodiment, the membrane may be eliminated entirely and the
solution may directly enter the cavity.
[0091] Alternatively or additionally, the outer covering of the
cochlear implant could be molded with features which facilitate the
retention of DEX and any carrier medium. By way of example and not
limitation the outer covering of the insulating silicone could be
molded with grooves, wells, indentations, or cavities. According to
one exemplary embodiment, a porous coating made from a hydrophilic
polymer covers the implant lead and is configured to be impregnated
with various drug eluting substances. In one illustrative
embodiment, a suspension of silicone and DEX could be inserted into
these features and transported into the cochlea, where the DEX
could be released into the intra cochlear space. In an alternative
embodiment, these features can be filled with drugs in a powered
form. A thin layer or layer of variable thickness of silicone or
other coating polymer could be applied to seal or partially seal
the hole to give rise to the desired release kinetics. A number of
factors could influence the release kinetics. By way of example and
not limitation, these factors could include the permeability of the
covering membrane to intracochlear or body fluids, the permeability
of the covering membrane to the drug or combination of drug in the
interior, the surface area of the covering membrane, the quantity
of drug powder, the solubility of the drug powder, the range of
particulate sizes in the powder, and other factors. As discussed
above, DEX salt, DXMb, and other therapeutic drugs could be
combined to deliver the desired therapeutic effect.
[0092] The various therapeutic drugs can be combined with polymers
in various geometries to assist in the desired delivery. For
example, in some circumstances, it may be desirable to control the
elution rate of various drugs by overcoating the drug layers with a
polymeric layer. According to one embodiment, the overcoating
polymeric layer may be deposited by vapor or plasma deposition of
the polymer agent to create a porous membrane. This allows the
deposition of the overcoat without the use of solvents, catalysts,
heat or other chemicals or techniques which would cause damage to
the agent, drug, or material. The polymeric overcoat layer can
allow for less retention of unused drug within in the implanted
device. Additionally, the polymeric overcoat can prevent
undesirable fragmentation of biodegradable interior substances.
[0093] In conjunction with the methods mentioned above, a variety
of surface treatments can be used to render the surface more
amenable to the subsequent processes. By way of example and not
limitation, these methods can include cleaning physical
modifications such as etching, drilling, cutting, or abrasion; and
chemical modifications such as solvent treatment, the application
of primer coatings, the application of surfactants, plasma
treatment, ion bombardment, and covalent bonding.
[0094] By way of example and not limitation, examples of
biodegradable polymers which can be used as a matrix to contain and
dispense various therapeutic compounds may be selected from
suitable members of the following, among many others: (a) polyester
homopolymers and copolymers such as polyglycolide, poly-L-lactide,
poly-D-lactide, poly-D,L-lactide, poly(beta-hydroxybutyrate),
poly-D-gluconate, poly-L-gluconate, poly-D,L-gluconate,
poly(epsilon caprolactone), poly(delta-valerolactone),
poly(p-dioxanone), poly(trimethylene carbonate),
poly(lactide-co-glycolide) (PLGA),
poly(lactide-co-delta-valerolactone),
poly(lactide-co-epsilon-caprolactone), poly(lactide-co-beta-malic
acid), poly(lactide-co-trimethylene carbonate),
poly(glycolide-co-trimethylene carbonate),
poly(beta-hydroxybutyrate-co-beta-hydroxyvalerate),
poly[1,3-bis(p-carboxyphenoxy)propane-co-sebacic acid], and
poly(sebacic acid-co-fumaric acid), among others, (b) poly(ortho
esters) such as those synthesized by copolymerization of various
diketene acetals and diols, among others, (c) polyanhydrides such
as poly(adipic anhydride), poly(suberic anhydride), poly(sebacic
anhydride), poly(dodecaned oic anhydride), poly(maleic anhydride),
poly[1,3-bis(p-carboxyphenoxy)methane anhydride], and
poly[alpha,omega-bis (p-carboxyphenoxy)alkane anhydrides] such
aspoly[1,3-bis(p-carboxyphenoxy)propane anhydride] and
poly[1,3-bis(p-carboxyphenoxy)hexane anhydride], among others; and
(d) amino-acid-based polymers including tyrosine-based polyarylates
(e.g., copolymers of a diphenol and a diacid linked by ester bonds,
with diphenols selected, for instance, from ethyl, butyl, hexyl,
octyl and bezyl esters of desaminotyrosyl-tyrosine and diacids
selected, for instance, from succinic, glutaric, adipic, suberic
and sebacic acid), tyrosine-based polycarbonates (e.g., copolymers
formed by the condensation polymerization of phosgene and a
diphenol selected, for instance, from ethyl, butyl, hexyl, octyl
and bezyl esters of desaminotyrosyl-tyrosine), and tyrosine-,
leucine- and lysine-based polyester-amides; specific examples of
tyrosine-based polymers include includes polymers that are
comprised of a combination of desaminotyrosyl tyrosine hexyl ester,
desaminotyrosyl tyrosine, and various di-acids, for example,
succinic acid and adipic acid, among others.
[0095] According to one embodiment, DXMb may also be delivered in
bio-release polymer matrix. The bio-release polymer matrix
containing DXMb may be used and shaped in a variety of ways. By way
of example and not limitation, a cochlear implant electrode array
coated with a DXMb impregnated polymer that can bio-release this
drug at a predetermined rate that is determined at the time of
fabrication.
[0096] According to one exemplary embodiment, the various drug
components can be incorporated into a polymeric matrix, which is
then applied to the cochlear lead. The polymeric matrix layer may
be fabricated in a variety of ways. By way of example and not
limitation, a mixture can be formed from 0.2 milligrams of
dexamethasone sodium phosphate with 0.5 cubic centimeters of
silicone medical adhesive. The mixture is molded to the desired
shape and allowed to cure. After curing the polymeric matrix layer
is attached to the outer substrate with silicone medical adhesive
such as SILASTIC by Dow Corning. The thickness of the drug
impregnated polymeric coating can be varied to deliver the optimal
amount of drug dosage over the lifetime of the device. The coating
may also cover varying portions of the implant. For example, the
coating may cover the entire implant lead or may be applied to only
a portion of the lead so that the electrodes are not covered.
[0097] Polymer matrix which as been impregnated with DXMb or
another drug can be shaped into a variety of geometries and
incorporated into a cavity within the lead. This cavity may be
covered by a porous elution path. The porous elution path may be
created by placing a layer of cindered platinum or titanium foam
over the cavity opening. According to one embodiment, the particles
of DEX salts or DXMb, combinations there of, can be mixed with
silicone rubber medical adhesive. The silicon rubber medical
adhesive is permeable by water vapor, which dissolves the DEX salts
or DXMb. The dissolved DEX salts or DXMb then elute from the matrix
into the cochlear space. In one illustrative embodiment, particles
of dexamethasone sodium phosphate, which has a relatively fast
elution rate, and particles of DXMb, which has a much slower
elution rate, can be use in combination to achieve the desired
release profile. As mentioned above, a number of other factors,
such as particle size, surface area, matrix, etc. can be used to
further adjust the drug release over time.
[0098] In an alternative embodiment, a silicone elastomer matrix is
used rather than silicon medical adhesive. The silicon elastomer
may provide a number of manufacturing advantages including longer
pot life and a shorter curing time. According to one illustrative
method, two silicon elastomer precursor compounds are combined with
a third compound which carries the drug particles. The third
compound may be silicone fluid and the drug particles may be made
up of DXMb or similar compound. The three components are mixed and
placed in a mold. The temperature of the matrix and mold can be
controlled to assist in curing the matrix. After the molding
process is complete, the silicon shape can be placed in or on the
cochlear lead as desired.
[0099] All of the above methods of dispensing therapeutic compounds
can be combined with various lubrication techniques. Additionally,
the drug layer may have lubricant properties or a lubrication layer
which contains drug compounds may be included.
[0100] FIGS. 16 and 17 show an illustrative embodiment of a
cochlear lead (1600) with various electrodes (1610) along one side
and a lumen (1605) passing longitudinally through the cochlear
lead. The lumen (1605) may access the surrounding tissues through
one or more apertures (1615). According to one embodiment, the
lumen (1605) may serve as a drug reservoir. For example, the lumen
(1605) could contain a powdered DEX salt (1620) near the aperture
(1615) and powdered DXMb (1625) in the remainder of the lumen
(1605). The aperture (1615) could be covered with a membrane (1630)
to retain the drug powders (1620, 1625) and control the passage of
solutes and particles through the aperture (1615). Additionally or
alternatively, the lumen (1605) could be filled with a suspension
of silicone and DEX salt/DXMb. The lumen could be filled with the
drug or drug eluting compound during manufacturing or just prior to
use.
[0101] FIGS. 18A and 18B are a top view and cross-sectional
diagram, respectively, of illustrative dispensing mechanism for
pharmaceutical agents. According to one illustrative embodiment, a
solid tablet (1820) of steroid is contained within a housing
(1805). An aperture (1810) in one side of the housing (1805) is
covered with a membrane (1815). When implanted in conjunction with
a medical device, the solid tablet (1820) of steroid is gradually
dissolved and elutes through the membrane into the body.
[0102] According to one illustrative embodiment, the tablet (1820)
is has a cylindrical shape with dimensions of approximately 1.5 mm
in diameter and 1.5 mm in height. The tablet (1820) may contain
approximately 0.5 milligrams of steroid and elute approximately 0.6
to 0.3 micrograms per day into the surrounding tissues over the
course of 30 months. The tablet may be comprised of a number of
steroid or other medications. By way of example and not limitation,
the tablet may comprise dexamethasone base or fluocinolone
acetonide.
[0103] The housing (1805) may be made of a variety of materials
that are biocompatible and have low permeability. For example, the
housing (1805) may be a silicone elastomer. The membrane (1815) may
be made from a variety of biocompatible materials that have higher
permeability, such as polyvinyl alcohol (PVA).
[0104] FIGS. 19 and 20 are a cross-sectional diagram and top view
of an illustrative cochlear lead that incorporates a tablet similar
to that described in FIG. 18. In this illustrative embodiment, the
silicone body of the cochlear lead (1900) forms the housing for the
tablet (1820). An aperture (1905) is formed within the cochlear
lead (1900). The tablet (1820) is placed within a cavity underlying
the aperture (1905) and the aperture is covered by a membrane
(1815). According to one embodiment, the membrane (1815) maintains
its structural integrity throughout the lifetime of the cochlear
lead. This prevents undissolved portions of the tablet from exiting
through the aperture.
[0105] In some embodiment, the tablet may be significantly smaller
than 1.5 mm. Additionally, multiple tablets may be incorporated
into the cochlear lead to achieve the desired drug combination and
release profile. In some circumstances, an active drug releasing
tablet may not be inserted into a cavity (1920). Instead, the
cavity may be left empty or a placebo could be inserted into the
cavity (1920). Additionally or alternatively, other compounds, such
as DEX salt tablet (1915) or other therapies can be inserted into
one or more of the cavities. For example, therapies which support
regrowth of hair cells or containing stem cells could be contained
within one or more of the cavities. This modularity allows the
cochlear lead to be customized for the particular needs of the
patient and leaves flexibility to incorporate future advances in
beneficial therapies. The apertures and membranes covering the
apertures may be modified to permit the most effectual release
profiles of the therapies contained within the corresponding
cavities. For example, the membrane covering a therapy that
includes larger molecules may be thinner or more porous to allow
the molecules to diffuse through the membrane.
[0106] FIG. 21 shows a cochlear lead (2100) that has a longitudinal
cavity (2110) which is configured to receive a drug releasing
capsule (2130). The drug releasing capsule (2130) may be held in
place within the longitudinal cavity in a number of ways. By way of
example and not limitation, the capsule (2130) may be glued in
place with silicone medical adhesive or another biocompatible
adhesive. The adhesion between the drug release capsule (2130) and
the supporting structure may be optimized by using a variety of
surface treatments. Additionally or alternatively, the cavity
(2110) may incorporate a number of features, such as overhanging
walls, which mechanically secure the capsule (2130) in place.
[0107] The drug releasing capsule (2130) may be in a variety of
shapes and sizes that are compatible with connection to the
cochlear lead (2100). According to one illustrative embodiment, the
drug release capsule (2130) may have a rod shaped housing that
contains drugs or drug generating materials. The drug elutes
through a membrane (2140) into the surrounding tissues. As
discussed above, the membrane pores may be sized to prevent the
passage of bacteria or other contaminates. For example, pore sizes
of 0.2 microns or less substantially prevent bacterial ingress and
egress from the drug releasing capsule.
[0108] The drug releasing capsule (2130) may also have number of
alternative embodiments. By way of example and not limitation, the
capsule (2130) may comprise a matrix which encapsulates the drug.
The drug then gradually elutes form the matrix to deliver the
desired drug profile. In an alternative embodiment, a dry powdered
drug may be complete encapsulated by a flexible membranous
material. By way of example and not limitation, the flexible
membranous material may be porous PolyTetraFluoroEthylene (PTFE), a
silicone membrane, Fluorinated Ethylene Propylene (FEP), or
cellulose acetate. Additionally or alternatively, a fluid or
suspension of drug may be encapsulated by the flexible membranous
material. Other embodiments of the capsule (2130) may include a
micro-osmotic pump which dispenses a controlled amount of a liquid
drug. In some embodiments, the liquid drug may be dissolved in a
carrier fluid. In other embodiments, the liquid drug may comprise
drug particles in suspension.
[0109] The drug release profile can controlled using a number of
factors. These factors may include the dimensions of the capsule
(such as length, diameter, cross-sectional geometry, etc.); the
placement of the membrane on the capsule; and membrane
characteristics (such as thickness, surface area, permeability,
pore size, etc.). The drug placed within the capsule can also
influence the release profile. As mentioned above, a combination of
DXMB and DEX salt powders could be used. The ratio of DXMB to DEX
salt powders could be designed to achieve the desired drug release
profile. For example, increasing the amount of DEX salt powder
would increase the initial burst of drug upon implantation.
Increasing the amount of DXMB powder, which has a much lower
solubility in aqueous solutions, could extend the length of the
treatment. Additionally, the particle sizes of the drug powders
could be altered. For example, large particle sizes may decrease
the total surface area of the drug powder and slow the release of
drug, while smaller particle sizes increase the total surface area
and may increase the release rate of the drug. Microspheres are one
example of particles which could be used to influence a drug
release profile.
[0110] The placement of the particles within the capsule (2130)
could also influence the drug release. According to one
illustrative embodiment, the membrane (2140) may be positioned such
that a first portion of the capsule (2130) has more direct access
to the membrane (2140) than second portion of the capsule (2130).
Consequently, drug agents placed in the first portion of the
capsule could be expected to elute through the membrane (2140) in
greater proportion than drug agents placed in the second portion of
the capsule.
[0111] Additionally or alternatively, the capsule (2130) may
incorporate genetically engineered cells which absorb nutrients
from the tissue surrounding the implantation site and produce a
therapeutic agent. According to one embodiment, the genetically
engineered cells are contained within a polymer membrane capsule
which is inserted into the implantation site. The nutrients from
the surrounding tissues diffuse through the polymer membrane to
sustain the genetically engineered cells. The genetically
engineered cells then manufacture the therapeutic drug according to
the genetic instructions which have been inserted into their
genome. The therapeutic agent diffuses through the membrane and
into the surrounding tissues. This approach has the potential
advantages of a long lifetime, smaller capsule size, the ability to
continuously deliver freshly synthesized therapeutic agents, and
the ability to manufacture in situ a variety of therapeutic agents
that are unstable or otherwise difficult to effectively
administer.
[0112] The use of a modular tablet or capsule as a means of drug
delivery has a number of benefits and advantages. A first advantage
may be that the tablet or capsule design can be relatively
independent of the electrode design. For example, the capsule may
be constructed of different materials and by a different process
than the electrode. When compared to coating methods used to
deliver therapeutic agents, the capsule or tablet may have a
significantly smaller effect the lubricity of the electrode. A
second advantage is that the tablet or capsule can be tested
independent of the full device. This could decrease development
times and lower manufacturing costs. A third advantage may be that
the modularity of the system allows for the cochlear lead to be
customized to meet the individual medical needs of the patient. A
wide variety of therapeutic drugs or other pharmaceutical agents
could be inserted into the tablet or capsule. If no therapeutic
agent is desired, the preformed cavity could simply be filled with
a silicone blank. Fourth, the modularity of the system allows for
new innovations to be incorporated into a drug delivery tablet or
capsule and inserted into the cochlear lead without the need to
redesign and retest the entire system. The modularly also allows an
experienced third party vendor to make the tablet or capsule, which
could result in significant cost reduction. Fifth, the
incorporation of a modular capsule can simplify the process of
assembling the cochlear lead. When compared to the coating process,
which requires expensive coating equipment, the insertion of a
tablet or capsule into a preformed cavity is significantly less
complex and time consuming.
[0113] The preceding description has been presented only to
illustrate and describe embodiments and examples of the principles
described. This description is not intended to be exhaustive or to
limit these principles to any precise form disclosed. Many
modifications and variations are possible in light of the above
teaching.
* * * * *